title: Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder.
abstract: Attention-deficit/hyperactivity disorder (ADHD) often occurs along with other psychiatric disorders, with estimated comorbidity rates of 50--90%. Comorbidity greatly influences presentation, diagnosis and prognosis, complicates treatment and significantly increases the morbidity and disease burden of ADHD. Commonly co-occurring psychiatric disorders are disruptive behavior disorder, anxiety, depression, bipolar disorder and substance use disorders. This article provides a brief review of effective strategies for treating the most common psychiatric disorders associated with ADHD. This paper also discusses knowledge gaps in the understanding of treatment of comorbid disorders associated with ADHD, and directions for future research.
authors: Department of Psychiatry, State University of New York--Upstate Medical University, Syracuse, NY 13210 USA.
authors: Arun
authors: A
authors: Kunwar
authors: Mantosh
authors: M
authors: Dewan
authors: Stephen V
authors: SV
authors: Faraone
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000453:epidemiology; D016642:Bupropion / Q000627:therapeutic use*; D002648:Child; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000188:drug therapy; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology; D015995:Prevalence; D011437:Propylamines / Q000627:therapeutic use*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D018687:Antidepressive Agents, Second-Generation; D011437:Propylamines; D016642:Bupropion; D000069445:Atomoxetine Hydrochloride